Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8201-8207

  Yoshiura, Kenta ^a   Nakaoka, Takashi ^a   Nishishita, Toshihide ^a   Sato, Katsuaki ^d   Yamamoto, Akifumi ^b   Shimada, Shinji ^e   Saida, Toshiaki ^f   Kawakami, Yutaka ^c   Takahashi, Tsuneo A ^a   Fukuda, Hiroyuki ^a   Imajoh Ohmi, Shinobu ^a   Oyaizu, Naoki ^a   Yamashita, Naohide ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d RIKEN YOKOHAMA INSTITUTE   (Japan)

^e UNIVERSITY OF YAMANASHI   (Japan)

^f SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; AUTOIMMUNITY; CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; DENDRITIC CELL; ENDOTHELIUM CELL; GOOD CLINICAL PRACTICE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASE II; CELL LINE; CELL LINE, TUMOR; DENDRITIC CELLS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; NEOVASCULARIZATION, PHYSIOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 28144440647     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0816     Document Type: Article

References (41)

1. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29.
2. Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S. Towards patient-specific tumor antigen selection for vaccination, Immunol Rev 2002;188: 164-76.
3. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41.
4. Robbins PF, El-Gamil M, Li YF, et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92.
5. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176: 1453-7.
6. Tureci O, Sahin U, Schobert I, et al. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 1996;56:4766-72.
7. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-8.
8. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
9. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
10. Ono M, Watanabe K, Miyashita Y, Inagaki Y, Ueki H. A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases. J Dermatol Sci 1999;21:183-6.
11. Nagayama H, Sato K, Morishita M, et al. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 2003;13:521-30.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
13. Fairbanks G, Steck TL, Wallach DF. Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry 1971;10:2606-17.
14. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
15. Spicer SS, Sens MA, Tashian RE. Immunocytochemical demonstration of carbonic anhydrase in human epithelial cells. J Histochem Cytochem 1982;30: 864-73.
16. Kellner R, Lichtenfels R, Atkins D, et al. Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2002;2:1743-51.
17. Lichtenfels R, Kellner R, Atkins D, et al. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 2003; 1646:21-31.
18. Prasannan L, Misek DE, Hinderer R, Michon J, Geiger JD, Hanash SM. Identification of β-tubulin isoforms as tumor antigens in neuroblastoma. Clin Cancer Res 2000;6:3949-56.
19. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001; 61:7908-12.
20. Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001;1:890-8.
21. Lichtenfels R, Kellner R, Bukur J, et al. Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2002;2: 561-70.
22. Unwin RD, Harnden P, Pappin D, et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003;3:45-55.
23. Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 2004;53:139-43.
24. Hodi FS, Schmollinger JC, Soiffer RJ, et al. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci USA 2002;99:6919-24.
25. Kino-Ohsaki J, Nishimori I, Morita M, et al. Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjogren's syndrome. Gastroenterology 1996;110:1579-86.
26. Okazaki K, Uchida K, Ohana M, et al. Autoimmune-related pancreatitis is associated with autoantibodies and aTh1/Th2-type cellular immune response. Gastroenterology 2000;118:573-81.
27. Invernizzi P, Battezzati PM, Crosignani A, et al. Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin Exp Immunol 1998;114:448-54.
28. Ueno Y, Ishii M, Igarashi T, et al. Primary biliary cirrhosis with antibody against carbonic anhydrase II associates with distinct immunological backgrounds. Hepatol Res 2001;20:18-27.
29. Taniguchi T, Okazaki K, Okamoto M, Seko S, Uchida K, Seino Y. Presence of autoantibodies to carbonic anhydrase II and lactoferrin in type 1 diabetes: proposal of the concept of autoimmune exocrinopathy and endocrinopathy of the pancreas. Diabetes Care 2001: 24:1695-6.
30. Andoh A, Fujiyama Y, Yoshioka U, et al. Elevated serum anti-carbonic anhydrase II antibodies in patients with ulcerative colitis. Int J Mol Med 2002;9: 499-502.
31. Parkkila AK, Herva R, Parkkila S, Rajaniemi H. Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours. Histochem J 1995;27:974-82.
32. Leppilampi M, Koistinen P, Savolainen ER, et al. The expression of carbonic anhydrase II in hematological malignancies. Clin Cancer Res 2002;8:2240-5.
33. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
34. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001;61:6020-4.
35. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
36. Alvarez L, Fanjul M, Carter N, Hollande E. Carbonic anhydrase II associated with plasma membrane in a human pancreatic duct cell line (CAPAN-1). J Histochem Cytochem 2001;49:1045-53.
37. Nishimori I, Bratanova T, Toshkov I, et al. Induction of experimental autoimmune sialoadenitis by immunization of PL/J mice with carbonic anhydrase II. J Immunol 1995;154:4865-73.
38. Ueno Y, Ishii M, Takahashi S, Igarashi T, Toyota T, LaRusso NF. Different susceptibility of mice to immune-mediated cholangitis induced by immunization with carbonic anhydrase II. Lab Invest 1998;78: 629-37.
39. Uchida K, Okazaki K, Nishi T, et al. Experimental immune-mediated pancreatitis in neonatally thymectomized mice immunized with carbonic anhydrase II and lactoferrin. Lab Invest 2002;82:411-24.
40. Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: synthesis of N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV. Bioorg Med Chem Lett 2000;10:1117-20.
41. Supuran CT, Briganti F, Tilli S, Chegwidden WR, Scozzafava A. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg Med Chem 2001; 9:703-14.